12:00 AM
 | 
May 30, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabometyx cabozantinib: Phase II data

Top-line data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced RCC showed that first-line treatment with once-daily 60 mg oral Cabometyx met the primary endpoint of improving PFS vs. Sutent sunitinib. The trial was conducted by the Alliance for Clinical Trials...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >